Search

Your search keyword '"Drospirenone -- Intellectual property"' showing total 10 results
Start Over Descriptor "Drospirenone -- Intellectual property" Topic contraceptives -- intellectual property
10 results on '"Drospirenone -- Intellectual property"'

1. Researchers Submit Patent Application, 'Use Of Combined Oral Contraceptives Containing Nomegestrol Acetate And Estradiol', for Approval (USPTO 20230398127)

Subjects
Estradiol -- Intellectual property, Women -- Health aspects, Drospirenone -- Intellectual property, Phenols -- Intellectual property, Contraceptives -- Intellectual property, Acetates -- Intellectual property, Health, Women's issues/gender studies
Abstract

2024 JAN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- From Washington, D.C., NewsRx journalists report that a patent application by the inventor BOOLELL, [...]

Published
2024

2. Researchers Submit Patent Application, 'Methods Of Contraception Using Nomegestrol Acetate And Estradiol', for Approval (USPTO 20230390306)

Subjects
Estradiol -- Intellectual property, Women -- Health aspects, Drospirenone -- Intellectual property, Phenols -- Intellectual property, Contraceptives -- Intellectual property, Norgestimate -- Intellectual property, Transdermal medication -- Intellectual property, Acetates -- Intellectual property, Health, Women's issues/gender studies
Abstract

2023 DEC 28 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- From Washington, D.C., NewsRx journalists report that a patent application by the inventor BOOLELL, [...]

Published
2023

3. 'Multiphasic Contraceptive Regimen For Oral Combination Drug Formulation Of Progestin And Estrogen' in Patent Application Approval Process (USPTO 20210346397)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Phenols -- Intellectual property, Norgestimate -- Intellectual property, Contraceptives -- Intellectual property, Drug approval, Estrogen, Health, Women's issues/gender studies
Abstract

2021 DEC 2 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent application by the inventor RUBIN, Arkady (Flemington, NJ, US), filed on July [...]

Published
2021

4. Patent Issued for Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen (USPTO 11103515)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Phenols -- Intellectual property, Norgestimate -- Intellectual property, Contraceptives -- Intellectual property, Estrogen, Health, Women's issues/gender studies
Abstract

2021 SEP 23 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent by the inventors Rubin, Arkady (Flemington, NJ, US), filed on December 10, [...]

Published
2021

5. Patent Application Titled 'Multiphasic Contraceptive Regimen For Oral Combination Drug Formulation Of Progestin And Estrogen' Published Online (USPTO 20200147105)

Subjects
Dienogest, Women's health, Estrogens, Drospirenone -- Intellectual property, Contraceptives -- Intellectual property, Phenols (Class of compounds) -- Intellectual property, Oral contraceptives, Health, Editors, Norgestimate, Health, Women's issues/gender studies
Abstract

2020 JUN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application [...]

Published
2020

6. Patent Issued for Multiphasic Contraceptive Regimen For Oral Combination Drug Formulation Of Progestin And Estrogen (USPTO 10,537,582)

Subjects
Dienogest, Women's health, Estrogens, Drospirenone -- Intellectual property, Contraceptives -- Intellectual property, Phenols (Class of compounds) -- Intellectual property, Oral contraceptives, Health, Editors, Norgestimate, Health, Women's issues/gender studies
Abstract

2020 FEB 6 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by [...]

Published
2020

7. Australian Patent Office Decision: Bayer Pharma Aktiengesellschaft [2022] APO 7 (7 February 2022)

Subjects
Merck Sharp & Dohme Corp. -- Intellectual property, Drospirenone -- Intellectual property, Contraceptives -- Intellectual property, Patents, Ethinyl estradiol -- Intellectual property, Pharmaceutical industry -- Intellectual property, Patent/copyright issue, News, opinion and commentary
Abstract

Canberra: Australian Patent Office has issued the following decision: AUSTRALIAN PATENT OFFICE Bayer Pharma Aktiengesellschaft [2022] APO 7 Patent: 780330 Title: Pharmaceutical combination of ethinylestradiol and drospirenone for use as [...]

Published
2022

8. Patent Issued for Multiphasic Contraceptive Regimen For Oral Combination Drug Formulation Of Progestin And Estrogen (USPTO 10,463,678)

Subjects
Dienogest, Women's health, Estrogens, Drospirenone -- Intellectual property, Contraceptives -- Intellectual property, Phenols (Class of compounds) -- Intellectual property, Oral contraceptives, Health, Editors, Norgestimate, Health, Women's issues/gender studies
Abstract

2019 NOV 21 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Arstat Inc. (Flemington, New Jersey, United States) has been issued patent number 10,463,678, according [...]

Published
2019

9. Patent Application Titled 'Multiphasic Contraceptive Regimen For Oral Combination Drug Formulation Of Progestin And Estrogen' Published Online (USPTO 20190282587)

Subjects
Dienogest, Women's health, Estrogens, Drospirenone -- Intellectual property, Contraceptives -- Intellectual property, Phenols (Class of compounds) -- Intellectual property, Oral contraceptives, Health, Editors, Health, Women's issues/gender studies
Abstract

2019 OCT 10 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application [...]

Published
2019

10. Researchers Submit Patent Application, 'Multiphasic Contraceptive Regimen For Oral Combination Drug Formulation Of Progestin And Estrogen', for Approval (USPTO 20190022109)

Subjects
Estrogens, Drospirenone -- Intellectual property, Drug approval, Dienogest, Contraceptives -- Intellectual property, Phenols (Class of compounds) -- Intellectual property, Oral contraceptives, Sex hormones, Progestational hormones, Editors, Health
Abstract

2019 FEB 11 (NewsRx) -- By a News Reporter-Staff News Editor at OBGYN & Reproduction Week -- From Washington, D.C., NewsRx journalists report that a patent application by the inventor [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results